DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.
Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY.
Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA.
March 10-12, Dr. Wagner will be attending the Barclays 28th Annual Global Healthcare Conference hosted at the Loews Miami Beach Hotel in Miami Beach, FL.
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Source: Forte Biosciences, Inc.
Contacts
LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
